Daidzein conjugates are more bioavailable than genistein conjugates in rats

Abstract

This study compared the bioavailability of conjugates of the soy isoflavones genistein and daidzein in rats. Rats were given a single oral dose of a soy extract that provided 74 μmol genistein and 77 μmol daidzein/kg body wt (as conjugates). Plasma samples were obtained from treated and untreated rats; urine and focal samples were obtained before and after treatment. Isoflavones, equol (the main end product of bacterial degradation of daidzein), and 4-ethyl phenol (the main end product from genistein) were measured by HPLC. The plasma daidzein concentration was maximal at 2 h (9.5 ± 0.71 μmol/L) and was almost double that of genistein (P = 0.009). Between 2 and 15 h, the plasma daidzein concentration declined by 32%, but the concentration of genistein changed little. At 15 h, the concentrations of daidzein and genistein were not significantly different. Urinary excretion of daidzein over the 48-h postdose period was 17.4 ± 1.2% of the dose, but only 11.9 ± 1.1% of the genistein dose was excreted in urine. Equol excretion was 5.0 ± 1.5% of the daidzein dose, but 41.9 ± 5.0% of the genistein dose was excreted as 4-ethyl phenol. Fecal daidzein accounted for 2.3 ± 0.5% and fecal genistein for 3.4 ± 0.4% of the respective doses. It is concluded that conjugates of daidzein are more bioavailable than those of genistein, probably because of the greater resistance of the former to degradation by gut bacteria.